CR20210587A - Inhibidores de molécula pequeña de quinasa inductora de nf-kb - Google Patents

Inhibidores de molécula pequeña de quinasa inductora de nf-kb

Info

Publication number
CR20210587A
CR20210587A CR20210587A CR20210587A CR20210587A CR 20210587 A CR20210587 A CR 20210587A CR 20210587 A CR20210587 A CR 20210587A CR 20210587 A CR20210587 A CR 20210587A CR 20210587 A CR20210587 A CR 20210587A
Authority
CR
Costa Rica
Prior art keywords
disorders
compounds
small molecule
molecule inhibitors
inducing kinase
Prior art date
Application number
CR20210587A
Other languages
English (en)
Inventor
Wenying Chai
William M Jones
Kevin D Kreutter
J Kent Barbay
Aaron T Herrmann
Alec D Lebsack
Wendy Eccles
Alexander R Rovira
Ronald L Wolin
Paul J Krawczuk
Michael D Hack
Daniel J Pippel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20210587A publication Critical patent/CR20210587A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con compuestos que inhiben el NIK y composiciones farmacéuticas que comprenden tales compuestos y métodos para el uso de estos. Se prevé que estos compuestos y composiciones farmacéuticas son útiles para prevenir o tratar enfermedades tales como cáncer (tal como neoplasias de células B que incluyen leucemias, linfomas y mieloma), trastornos inflamatorios, trastornos autoinmunes, trastornos inmunodermatológicos tales como pustulosis palmoplantar e hidradenitis supurativa, y trastornos metabólicos tales como obesidad y diabetes
CR20210587A 2019-05-31 2020-05-29 Inhibidores de molécula pequeña de quinasa inductora de nf-kb CR20210587A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Publications (1)

Publication Number Publication Date
CR20210587A true CR20210587A (es) 2022-02-11

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210587A CR20210587A (es) 2019-05-31 2020-05-29 Inhibidores de molécula pequeña de quinasa inductora de nf-kb

Country Status (22)

Country Link
US (2) US11254673B2 (es)
EP (1) EP3976597A1 (es)
JP (1) JP2022534302A (es)
KR (1) KR20220027871A (es)
CN (1) CN114222737A (es)
AU (1) AU2020282005A1 (es)
BR (1) BR112021023796A2 (es)
CA (1) CA3143350A1 (es)
CL (1) CL2021003142A1 (es)
CO (1) CO2021017838A2 (es)
CR (1) CR20210587A (es)
DO (1) DOP2021000244A (es)
EC (1) ECSP21093623A (es)
IL (1) IL288387A (es)
JO (1) JOP20210318A1 (es)
MA (1) MA56038A (es)
MX (1) MX2021014679A (es)
PE (1) PE20220768A1 (es)
SG (1) SG11202112994WA (es)
TW (1) TW202110842A (es)
UY (1) UY38721A (es)
WO (1) WO2020239999A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210318A1 (ar) * 2019-05-31 2023-01-30 Janssen Pharmaceutica Nv مثبطات جزيئية صغيرة لكيناز تحفيز nf-?b
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023217906A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidinone derivatives as inhibitors of nf kappa b inducing kinase
WO2023217879A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
CN101213194A (zh) * 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
KR101227228B1 (ko) 2004-11-12 2013-01-28 스태츠 칩팩, 엘티디. 와이어 본드 배선
US20110086834A1 (en) 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
JP2014508183A (ja) * 2011-03-16 2014-04-03 エフ.ホフマン−ラ ロシュ アーゲー 6,5−複素環式プロパルギルアルコール化合物及びこれらの使用
KR20140131359A (ko) 2012-02-17 2014-11-12 에프. 호프만-라 로슈 아게 트라이사이클릭 화합물 및 이의 사용 방법
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX2016002238A (es) * 2013-08-22 2016-05-31 Hoffmann La Roche Alcoholes de alquilino y metodos de uso.
RU2016110021A (ru) * 2013-08-22 2017-09-27 Ф. Хоффманн-Ля Рош Аг Алкиниловые спирты и способы их применения
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
ES2718557T3 (es) 2014-10-23 2019-07-02 Janssen Pharmaceutica Nv Nuevos compuestos como inhibidores de nik
WO2016062790A1 (en) 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
BR112017008039B1 (pt) 2014-10-23 2023-04-11 Janssen Pharmaceutica N.V. Derivados de pirazol como inibidores de nik, seu uso no tratamento ou prevenção de câncer e composição farmacêutica que os compreende
CN107074881B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的噻吩并嘧啶衍生物
CN107406427A (zh) 2015-02-25 2017-11-28 豪夫迈·罗氏有限公司 炔基醇及其使用方法
JP6916796B2 (ja) 2016-01-22 2021-08-11 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新たな6員のヘテロ芳香族置換シアノインドリン誘導体
BR112018014675B1 (pt) 2016-01-22 2023-12-19 Janssen Pharmaceutica Nv Derivados de cianoindolina substituída como inibidores de nik e composição farmacêutica que os compreende
AU2017289317B2 (en) 2016-06-30 2021-04-01 Janssen Pharmaceutica Nv Cyanoindoline derivatives as NIK inhibitors
CN109641882B (zh) 2016-06-30 2022-10-28 杨森制药有限公司 作为nik抑制剂的杂芳族衍生物
CN109863142B (zh) 2016-08-24 2022-06-10 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ.ホフマン-ラ ロシュ アーゲー 2-アザビシクロ[3.1.0]ヘキサン-3-オン誘導体及び使用方法
KR102662373B1 (ko) 2017-07-06 2024-04-29 얀센 파마슈티카 엔브이 Nik 억제제로서의 신규 치환 아자인돌린 유도체
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物,其制备方法和用途
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202108571A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
CN113891745B (zh) 2019-05-31 2024-05-07 奇斯药制品公司 作为p2x3抑制剂的氨基喹唑啉衍生物
BR112021024033A2 (pt) 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
JOP20210318A1 (ar) * 2019-05-31 2023-01-30 Janssen Pharmaceutica Nv مثبطات جزيئية صغيرة لكيناز تحفيز nf-?b
TW202126652A (zh) 2019-09-30 2021-07-16 美商英塞特公司 作為免疫調節劑之吡啶并[3,2—d]嘧啶化合物

Also Published As

Publication number Publication date
US11254673B2 (en) 2022-02-22
JP2022534302A (ja) 2022-07-28
WO2020239999A1 (en) 2020-12-03
CL2021003142A1 (es) 2022-08-19
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
MA56038A (fr) 2022-04-06
CA3143350A1 (en) 2020-12-03
TW202110842A (zh) 2021-03-16
MX2021014679A (es) 2022-04-06
UY38721A (es) 2020-11-30
US20210300918A1 (en) 2021-09-30
KR20220027871A (ko) 2022-03-08
IL288387A (en) 2022-01-01
BR112021023796A2 (pt) 2022-02-08
PE20220768A1 (es) 2022-05-16
JOP20210318A1 (ar) 2023-01-30
DOP2021000244A (es) 2022-04-18
SG11202112994WA (en) 2021-12-30
US11827634B2 (en) 2023-11-28
CO2021017838A2 (es) 2022-01-17
EP3976597A1 (en) 2022-04-06
ECSP21093623A (es) 2022-01-31
US20230080834A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
MX2021014679A (es) Inhibidores de molécula pequeña de quinasa inductora de nf-kb.
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX2017005284A (es) Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk).
GEP20227442B (en) Boron containing pde4 inhibitors
MX2021013641A (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
BR112021022966A2 (pt) Método para reduzir o tamanho do tumor
MX2021005273A (es) Inhibidores de quinasa rock.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов
MX2023005681A (es) Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol.
MX2016013108A (es) Nueva composicion para el tratamiento de la tricomoniasis.
MY192305A (en) Bipyrazole derivatives as jak inhibitors
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors